brought forward but said that without knowing why NIH interpreted 
the NIH Guidelines the way they did in the Argentine experiment 
that it was difficult to know whether such an amendment was 
justified or not. Dr. Korwek said there were two questions to be 
asked: 
1. In the case of the Pseudorabies vaccine test, was this 
research funded with NIH funds with only minor private 
funding for the field test abroad? 
2. If all the loopholes are closed, as this proposal is 
seeking to do, will it not simply force companies and 
individuals to conduct their research abroad? 
Dr. Korwek added that such research will continue to occur and 
this proposal, "will not be an absolute mechanism to get 
applicability of the NIH Guidelines." He then asked Dr. Gartland 
for clarification on the NIH's decision on the Pseudorabies 
vaccine . 
Dr. Gartland said he could not add more than what was stated in 
letters which are already in the public record and that was the 
NIH did support research at the Wistar Institute. However, the 
NIH legal staff took the position that NIH money was not expended 
in Argentina; and, therefore, the field test was not supported by 
NIH. 
Mr. Mitchell reiterated once again the definition of the words 
"project" and "support" were unclear and that questions arise: 
(1) if an experiment is initiated in the U.S., must it be 
completed here; and (2) if it is initiated with NIH funds and 
completed abroad, are the NIH Guidelines sufficiently clear to 
reflect the intent of the RAC? 
Dr. Davis interjected that he preferred not to discuss the legal 
aspects and not to get into the ramifications of such research on 
U.S. international relations. He added that possibly the State 
Department should be consulted. He pointed out that Mr. Rif kin 
had made statements such as, "We don't want to make other 
countries a dumping ground for our junk." Dr. Davis said he felt 
other countries had rights. The U.S. is not forcing any country 
to permit testing. It is an internal decision in those countries 
to allow such experiments to take place. He said he felt that we 
should pass no rule which would prevent any country abroad from 
testing any strains which are produced using recombinant 
technology which they might find valuable. He asked whether we 
should set up rules which would restrict a country which may have 
an epidemic of a disease such as hoof and mouth disease from 
obtaining a strain of an attenuated vaccine which may solve their 
problem. He once again cited the Sabin polio vaccine and asked 
if the same vaccine were newly produced today using recombinant 
technology would we feel we had a need to protect the Soviets 
Recombinant DNA Research, Volume 13 
[51] 
